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Abstract
Background—Many public health laboratories adopting the U.S. HIV laboratory testing 
algorithm do not have a nucleic acid test (NAT), which is needed when the third-or fourth-
generation HIV screening immunoassay is reactive and the antibody-based supplemental test is 
non-reactive or indeterminate.
Objectives—Among public health laboratories utilizing public health referral laboratories for 
NAT conducted as part of the algorithm, we evaluated the percentage of screening immunoassays 
needing NAT, the number of specimens not meeting APTIMA (NAT) specifications, time to 
APTIMA result, the proportion of acute infections (i.e., reactive APTIMA) among total infections, 
and screening immunoassay specificity.
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Study Design—From August 2012 to April 2013, 22 laboratories enrolled to receive free 
APTIMA (NAT) at New York or Florida public health referral laboratories. Data were analyzed 
for testing conducted until June 2013.
Results: Submitting laboratories conducted a median of 4,778 screening immunoassays; 0 to 1.3% 
(median 0.2%) needed NAT. Of 140 specimens received, 9 (6.4%) did not meet NAT 
specifications. The median time from specimen collection to reporting the 11 reactive NAT results 
was ten days, including six days from receipt in the submitting laboratory to shipment to the 
referral laboratory. Acute infections ranged from 0 to 12.5% (median 0%) of total infections. 
Third- and fourth-generation immunoassays met package insert specificity values.
Conclusions—Public health referral laboratories provide a feasible option for conducting NAT. 
Reducing the time from specimen collection to submission of specimens for NAT is an important 
step toward maximizing the public health impact of identifying acute infections.
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Background
The HIV diagnostic testing algorithm recommended by the Centers for Disease Control and 
Prevention (CDC) and the Association of Public Health Laboratories (APHL) includes the 
use of a nucleic acid test (NAT) for specimens with a repeatedly reactive fourth-generation 
immunoassay and a non-reactive or indeterminate supplemental antibody test that 
differentiates HIV-1 from HIV-2. [1] If the NAT is negative, there is no evidence of HIV 
infection, and the result likely occurred due to a false-positive initial immunoassay. Fourth-
generation immunoassays, such as the ARCHITECT HIV Ag/Ab Combo (Abbott 
Diagnostics, Chicago, Illinois) (ARCHITECT) and the GS HIV Combo Ag/Ab EIA (Bio-
Rad Laboratories, Redmond, WA) (GS Combo), appear to perform with high specificity, [2–
4] so false-positive results should be rare. If the NAT is reactive, there is evidence of acute 
infection. Identification of acute infections enables timely intervention to treat infected 
persons and curb onward transmission. [5, 6]
Only one NAT is Food and Drug Administration (FDA)-approved for diagnostic use, the 
APTIMA HIV-1 RNA Qualitative Assay (APTIMA, Hologic GEN-PROBE, San Diego, 
CA). Low testing volumes in many laboratories make it impractical to maintain the test due 
to cost and required technical expertise. [7] The CDC and APHL conducted a demonstration 
project in which two public health laboratories provided NAT referral services for public 
health laboratories using the recommended algorithm.
Objectives
We assessed whether submitting laboratories adhered to APTIMA specimen handling 
instructions, the time to provision of APTIMA results, the proportion of acute infections, 
and the specificity of the third- and fourth-generation screening immunoassays.
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New York State Department of Health’s Wadsworth Center and the Florida Department of 
Health, Bureau of Public Health Laboratories were selected to serve as NAT referral 
laboratories because of their experience using APTIMA. APHL member laboratories using 
the laboratory algorithm with a repeatedly reactive third- or fourth-generation immunoassay 
and a non-reactive or indeterminate antibody supplemental test and without access to NAT 
were invited to participate at no cost. Although not preferred, third-generation 
immunoassays are listed as an alternative to fourth-generation immunoassays in the 
algorithm, [8] and Western blots and immunofluorescence assays are included as 
alternatives to supplemental antibody tests that differentiate HIV-1 from HIV-2. Between 
August 2012 and April 2013, 22 public health laboratories enrolled to send serum or plasma 
that required NAT to the referral laboratories. We examined data from enrollment until June 
2013. During that period, 15 public health laboratories used fourth-generation 
immunoassays: seven used ARCHITECT and eight used GS Combo. Six laboratories used 
third-generation immunoassays: five used GS HIV-1/HIV-2 Plus O EIA (Bio-Rad 
Laboratories, Redmond, WA) (GS Plus O) and one used ADVIA Centaur HIV1/O/2 
Enhanced (Ortho-Clinical Diagnostics, Tarrytown, NY) (ADVIA). One laboratory switched 
from a third-generation (GS HIV-1/HIV-2 Plus O EIA (Bio-Rad Laboratories, Redmond, 
WA)) to a fourth-generation immunoassay (ARCHITECT). For supplemental testing, eight 
laboratories used an HIV-1/HIV-2 differentiation test, ten used an HIV-1 Western blot, three 
used both, and one used an HIV-1 immunofluorescence assay and an HIV-2 Western blot.
The New York referral laboratory reported APTIMA results to the submitting laboratory by 
telephone or fax, and mailed a report. The Florida laboratory returned APTIMA results to 
the submitting laboratory by secure fax, and sent an email about the fax.
By submitting laboratory, we reported the number of specimens needing NAT. Nucleic acid 
tests, such as APTIMA, have more restrictive criteria for usage than serologic tests. We 
evaluated the proportion not meeting package insert requirements. We assessed the 
proportion of acute infections among total infections in each submitting laboratory. We 
conducted a sensitivity analysis for acute infections among total infections to assess the 
maximum proportion of acute infections. In this analysis, we considered specimens eligible 
for NAT testing that did not receive it, as well as submitted specimens with reactive NAT, to 
be acute infections. The occurrence of false-positive screening test results impacts how often 
NAT is needed. We calculated the specificity of each screening immunoassay by submitting 
laboratory. We conducted a sensitivity analysis that represented the worst case scenario for 
specificity, in which specimens with false-positive screening assay results based on NAT, 
and those eligible for NAT that did not receive it, were considered to have false-positive 
results. Finally, since timely provision of results among those with acute infection is 
paramount, we assessed the time from specimen collection to reporting of results, by 
APTIMA result.
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Submitting laboratories conducted between 486 and 39,257 third or fourth-generation 
immunoassay tests (median=4,778) (Table 1). From 0 % to 1.3% (median=0.2%) of 
specimens tested in each submitting laboratory needed NAT. Of those 290 specimens, 140 
(48.3%) were submitted to the referral laboratories. The median specimen volume sent was 
600µL.
Specimen adequacy for NAT
Of 140 specimens submitted, 9 (6.4%) were insufficient for testing because blood was stored 
for greater than 3 days before centrifugation (n=6), or because serum was held for more than 
8 days at 4°C or above in the submitting laboratory (n=3).
Infections during the study period
Laboratories reported between 8 and 460 total HIV infections (Table 1). The proportion of 
acute infections among total infections ranged from 0 to 12.5% (median=0%). According to 
the sensitivity analysis, the maximum proportion of acute infections among total infections 
ranged from 0 to 36.4% (median=12.9%). The highest percentage was from the laboratory 
with eight total infections. There was no evidence of testing more than one specimen from 
persons identified with acute infection, based on the laboratory information systems in New 
York, and given that no two specimens tested in Florida came from the same laboratory.
Screening assay specificity
The median specificity for all assays was > 99.9% (Table 2). The specificity confidence 
interval for all screening immunoassays overlapped with or was higher than that listed in the 
package insert (not shown), except for one ’worst case’ estimate for specificity for the GS 
HIV-1/HIV-2 Plus O EIA (98.7%).
Time to APTIMA results
The time from specimen collection to APTIMA result reporting was 11 days for those with 
non-reactive results and 10 days for those with reactive results (Table 3). The time from 
specimen receipt at the submitting laboratory to shipment to the referral laboratory was the 
biggest lag, and took six days. Referral laboratories tested specimens with APTIMA within 
two days.
Discussion
During the study, 22 laboratories using the recommended HIV diagnostic testing algorithm 
enrolled to receive NAT, which is indicative of the need for alternative NAT sources for 
public health laboratories. Approximately 0.2% of specimens tested needed NAT, and third- 
and fourth-generation immunoassays performed with high specificity. Thus, it may not be 
cost-effective for public health laboratories to implement NAT in-house. Most specimens 
submitted to public health referral laboratories were suitable for APTIMA testing. Eleven 
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acute infections were identified, some of which occurred in areas with low rates (i.e., <1%) 
of established infection.
The time from specimen collection to release of results from the referral laboratory was ten 
days for specimens from persons with acute infection, and there may have been subsequent 
delays in getting results to infected persons. Test results should be returned quickly to 
maximize the benefit of identifying persons with acute infection by linking them to care and 
treatment, counseling them to reduce risk behaviors that lead to transmission, and so that 
their partners can be offered testing. [9, 10] Although acute infections constituted less than 
13% of infections for any laboratory, early infections are linked with a disproportionate 
number of transmissions relative to established infections, due to high viral loads during that 
period. [6, 11] The number of days the specimens remained in the submitting laboratory 
before shipment to the referral laboratory accounted for most of the delay. Some of this time 
reflected testing with the initial and supplemental IAs; whether specimens were held after 
testing until shipment to the referral laboratory is unknown. Time to shipment to the referral 
laboratory should decrease if laboratories using the Western blot adopt the HIV-1/HIV-2 
rapid test. Specimens were swiftly processed and tested in the referral laboratories. 
However, in one case, staffing shortages, which were resolved, caused a 12-day processing 
time for a NAT non-reactive specimen.
Public health laboratories using the recommended algorithm may need sources of NAT 
other than public health referral laboratories. They may be able to partner with local 
laboratories implementing NAT, [12] which will require establishing methods for payment, 
and ensuring that partner laboratories maintain quality assurance, and return results rapidly. 
Commercial laboratories can provide a diagnostic NAT, but may be costly or have long 
turnaround times. If a quantitative HIV-1 NAT is FDA-approved for diagnostic use, 
laboratories will be able to run diagnostic testing as well as monitor disease progression and 
treatment, but this may not be cost-effective for laboratories that do not routinely perform 
tests to follow clinical status. Alternatively, persons with discordant results needing NAT 
could be referred to a clinical setting for resolution of infection status since a quantitative 
NAT can be ordered by a physician. Finally, HIV-1 nucleic acid tests are in development 
that may be conducted at the point of care, which would expedite the provision of results to 
persons with acute infection, and, likely reduce costs. [13–15]
Almost half of the specimens needing NAT were not submitted to a referral laboratory. 
Multiple specimens needing NAT may have come from the same individual, and so one 
NAT would sufficiently resolve infection status. Participating laboratories and testing 
programs should work together to identify the reasons for specimens not receiving NAT, as 
persons being tested may be acutely infected. The reasons specimens were not submitted for 
NAT were not recorded, but likely included specimen storage outside of test specifications, 
insufficient residual volumes, and persons not returning to submit an additional specimen. 
With the use of the recommended algorithm, increased serum or plasma is needed from all 
persons tested in case NAT is required, so that delays associated with subsequent specimen 
collections are avoided. Specimens must be held according to the specifications for all tests 
conducted in the algorithm. This may require modifying specimen collection protocols and 
apprising phlebotomy and laboratory staff of the changes. Plasma is needed if a doctor 
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orders a quantitative nucleic acid test, but APTIMA can be used with serum or plasma. The 
updated CDC/APHL guidance recommends that 2mL of serum or plasma be collected to 
conduct all assays in the algorithm. [1]
There were some limitations to our study. The conditions of the specimens at the collection 
site were unknown. In addition, this project did not capture whether the submitting 
laboratories that used only the HIV-1 Western blot for supplemental testing sent specimens 
with a reactive third-or fourth-generation assay and a negative or indeterminate HIV-1 
Western blot and a negative HIV-1 NAT for further HIV-2 testing, as recommended in 
CDC/APHL guidance. [1]
Overall, most specimens received by the public health referral laboratories met APTIMA 
package insert requirements and turnaround time at the referral laboratories was rapid. 
However, overall time from specimen collection to reporting of test results for specimens 
from persons with acute infections was suboptimal to expedite care and services, and to 
prevent transmission. Laboratories using the recommended algorithm should work to 
complete all aspects of testing, referral and reporting of specimens in a timely manner to 
obtain the maximum public health benefit. Alternative NAT sources should also be 
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Table 2
Specificity of third- and fourth-generation immunoassays in 19 public health laboratoriesa participating in the 
nucleic acid testing referral program




ARCHITECT HIV Ag/Ab Combo (6) 99.9% (99.9%, 100%) 99.9% (99.7%, 99.9%)
GS HIV Combo Ag/Ab EIA (8) 100% (99.8%, 100%) 99.9% (99.8%, 100%)
GS HIV-1/HIV-2 Plus O EIA (5) 100% (99.8%, 100%) 99.9% (98.7%, 100%)
a
Specificity of the Advia Centaur could not be calculated as the site using it did not submit data. Specificity of the two screening immunoassays 
could not be assessed in the site that switched assays as the site did not separate testing data by screening assay. One site using the ARCHITECT 
did not submit data required to calculate specificity.
b
Specificity (for screening immunoassay (IA) at each submitting laboratory)= IA negative/ [IA negative +(IA false positive)] where IA false 
positive=number with repeatedly reactive IA, negative or indeterminate supplemental antibody test, and negative NAT. The median, minimum and 
maximum were calculated based on the specificity in laboratories using the specified assay.
c
Calculated as specificity in which IA false positive= (number with repeatedly reactive IA, negative or indeterminate supplemental antibody test, 
and negative NAT) PLUS (number specimens eligible for NAT testing that did not receive it). The median, minimum and maximum were 
calculated based on the specificity in laboratories using the specified assay.
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Table 3
Time from specimen collection to reporting of APTIMA (NAT) test results by the referral laboratory (n=131 
specimens from 22 public health laboratories)
Process Step Median Days
(Minimum, Maximum)a
Specimen collection to receipt in the submitting laboratory 1 (0,13)
Receipt in the submitting laboratory to shipment to referral laboratory 6 (0,60)
Shipment 1 (1,5)
Receipt in referral laboratory to test result 2 (0,12)
Test result to reporting for specimens with reactive NAT
Test result to reporting for specimens with non-reactive NAT
0 (0,1)
0 (0,3)
Total time from specimen collection to NAT result reporting, reactive NAT




Minimum and maximum across the public health laboratories
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